ArticleAdvances in Diabetes and Heart Disease From ESC 2022Author:Pardeep Jhund, MDPublish date: September 19, 2022The mortality risk of diabetes, the consistent efficacy of dapagliflozin, and adherence to SGLT2 inhibitors ...Read More
